Abstract
Research in cancer immunology is currently accelerating following a series of cancer immunotherapy breakthroughs during the last 5 years. Various monoclonal antibodies which block the interaction between checkpoint molecules PD-1...
Highlights
Non-small cell lung cancer (NSCLC) is by far the leading cause of cancer related mortality in the US and worldwide [1, 2]
T-cell markers, but not B- or NK-cell markers, were noted to drop by day 2 of treatment, but increased substantially and remained elevated for about 30 days. These findings suggested that the effects of nivolumab treatment were rapid and resulted in a major redistribution of existing lymphocytes, followed by a prolonged period of immune activation which correlated with the anti-tumor response [9]
It appears that both antiPD-1 antibodies, as well as the therapeutic anti-programmed death ligand 1 (PD-L1) antibodies in development, will have comparable efficacy and toxicity, with responses in approximately 15–20 % of unselected NSCLC patients and serious autoimmune toxicities in 5–10 % of patients
Summary
Non-small cell lung cancer (NSCLC) is by far the leading cause of cancer related mortality in the US and worldwide [1, 2]. T-cell markers, but not B- or NK-cell markers, were noted to drop by day 2 of treatment, but increased substantially and remained elevated for about 30 days These findings suggested that the effects of nivolumab treatment were rapid and resulted in a major redistribution of existing lymphocytes, followed by a prolonged period of immune activation which correlated with the anti-tumor response [9]. Serious AEs occurred in 11 % of all patients including two deaths in the NSCLC cohort due to pneumonitis These early deaths may have been preventable with earlier intervention, as the autoimmune toxicities of the drugs were still poorly understood at the time. Treatment toxicity was higher in this population, 27 % of patients required a dose delay and 17 % experienced a treatment related grade 3 or 4 AE, including four patients with pneumonitis and three with colitis. The most common immune-related toxicities were hypothyroidism, colitis, pneumonitis, nephritis, and rash, each occurring at a rate of about 4–8 % (all grades), and there were no immune-related deaths
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
